From: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
Patient characteristics | n | Median bPFS (months) | p-value | Median cPFS (months) | p-value |
---|---|---|---|---|---|
Age at diagnosis of oligometastases | Â | Â | 0.007 | Â | 0.008 |
 ≤ 70 years | 33 | 34.3 |  | Not reached |  |
 > 70 years | 47 | 13.4 |  | 15.0 |  |
Gleason score | Â | Â | 0.622 | Â | 0.877 |
 ≤ 8 | 40 | 18.3 |  | 21.6 |  |
 ≥ 9 | 40 | 15.9 |  | 18.5 |  |
Initial tumor stage | Â | Â | 0.710 | Â | 0.601 |
 ≤ T2 | 24 | 18.3 |  | 21.6 |  |
 ≥ T3 | 54 | 16.5 |  | 21.5 |  |
Initial nodal stage | Â | Â | 0.658 | Â | 0.227 |
 N0 | 51 | 15.9 |  | 17.5 |  |
 N1 | 21 | 21.2 |  | 80.1 |  |
PSA-DT | Â | Â | 0.928 | Â | 0.952 |
 ≤ 4 months | 24 | 15.9 |  | 19.0 |  |
 > 4 months | 25 | 13.6 |  | 15.2 |  |
Number of metastases | Â | Â | 0.471 | Â | 0.413 |
 1 | 53 | 16.1 |  | 18.5 |  |
 ≥ 2 | 27 | 16.5 |  | 34.8 |  |
Hormone-sensitivity | Â | Â | 0.052 | Â | 0.040 |
 HSPC | 62 | 21.2 |  | 26.5 |  |
 CRPC | 18 | 12.0 |  | 12.8 |  |
Category of oligometastatic disease | Â | Â | 0.003 | Â | 0.003 |
 De-novo synchronous oligometastatic disease | 25 | 34.3 |  | 80.9 |  |
 De-novo metachronous oligorecurrent disease | 37 | 16.1 |  | 19.0 |  |
 Other (de-novo oligoprogressive, repeat oligometastatic or induced oligometastatic disease) | 18 | 10.3 |  | 12.4 |  |
Concomitant ADT | Â | Â | 0.000007 | Â | 0.000149 |
 Present | 55 | 26.0 |  | 34.8 |  |
 Absent | 25 | 9.2 |  | 12.4 |  |
Dose BED3 | Â | Â | 0.142 | Â | 0.102 |
 ≤ 93 Gy | 31 | 26.0 |  | 17.3 |  |
 > 93 Gy | 49 | 13.9 |  | 80.9 |  |